Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections

被引:416
作者
Tamma, Pranita D. [1 ]
Aitken, Samuel L. [2 ]
Bonomo, Robert A. [3 ,4 ,5 ]
Mathers, Amy J. [6 ,7 ]
van Duin, David [8 ]
Clancy, Cornelius J. [9 ]
机构
[1] Johns Hopkins Univ, Dept Pediat, Sch Med, Baltimore, MD USA
[2] Univ Michigan Hlth, Dept Pharm, Ann Arbor, MI USA
[3] Univ Hosp Cleveland Med Ctr, Louis Stokes Cleveland Vet Affairs Med Ctr, Med Serv, Cleveland, OH USA
[4] Univ Hosp Cleveland Med Ctr, Louis Stokes Cleveland Vet Affairs Med Ctr, Ctr Antimicrobial Resistance & Epidemiol, Cleveland, OH USA
[5] Case Western Reserve Univ, Dept Med Pharmacol Mol Biol & Microbiol, Cleveland, OH USA
[6] Univ Virginia, Dept Med, Charlottesville, VA USA
[7] Univ Virginia, Dept Pathol, Charlottesville, VA USA
[8] Univ North Carolina, Dept Med, Sch Med, Chapel Hill, NC USA
[9] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA
关键词
ESBL; carbapenem-resistant Enterobacterales; Pseudomonas aeruginosa; CRAB; Stenotrophomonas maltophilia; SPECTRUM-BETA-LACTAMASE; VENTILATOR-ASSOCIATED PNEUMONIA; IN-VITRO ACTIVITY; BLOOD-STREAM INFECTIONS; URINARY-TRACT-INFECTIONS; CRITICALLY-ILL PATIENTS; COMPLICATED INTRAABDOMINAL INFECTIONS; CEFTAZIDIME-AVIBACTAM RESISTANCE; US MEDICAL-CENTERS; CARE-ASSOCIATED INFECTIONS;
D O I
10.1093/cid/ciad428
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The Infectious Diseases Society of America is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance document focuses on infections caused by extended-spectrum beta-lactamase-producing Enterobacterales, AmpC beta-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia. This updated document replaces previous versions of the guidance document. Methods: A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections formulated questions about the treatment of infections caused by extended-spectrum beta-lactamase-producing Enterobacterales, AmpC beta-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, carbapenem-resistant Acinetobacter baumannii, and S. maltophilia. Because of differences in the epidemiology of resistance and availability of specific anti-infectives internationally, this document focuses on the treatment of infections in the United States. Results: Preferred and alternative suggested treatment approaches are provided with accompanying rationales, assuming the causative organism has been identified and antibiotic susceptibility results are known. Approaches to empiric treatment, transitioning to oral therapy, duration of therapy, and other management considerations are also discussed briefly. Suggested approaches apply for both adult and pediatric populations, although suggested antibiotic dosages are provided only for adults. Conclusions: The field of antimicrobial-resistance is highly dynamic. Consultation with an infectious diseases specialist is recommended for the treatment of antimicrobial resistant infections. This document is current as of 31 December 2022 and will be updated periodically. The most current version of this document, including date of publication, is available at www.idsociety.org/practice-guideline/amr-guidance/.
引用
收藏
页数:53
相关论文
共 703 条
[41]   In vitro killing of parenteral beta-lactams against standard and high mocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae [J].
Burgess, DS ;
Hall, RG .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2004, 49 (01) :41-46
[42]  
Burkhardt O, 2007, J ANTIMICROB CHEMOTH, V59, P277, DOI [10.1093/jac/dk1485, 10.1093/jac/dkl485]
[43]   KINETIC INTERACTIONS OF TAZOBACTAM WITH BETA-LACTAMASES FROM ALL MAJOR STRUCTURAL CLASSES [J].
BUSH, K ;
MACALINTAL, C ;
RASMUSSEN, BA ;
LEE, VJ ;
YANG, YJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (04) :851-858
[44]   Epidemiology of β-Lactamase-Producing Pathogens [J].
Bush, Karen ;
Bradford, Patricia A. .
CLINICAL MICROBIOLOGY REVIEWS, 2020, 33 (02)
[45]   Updated Functional Classification of β-Lactamases [J].
Bush, Karen ;
Jacoby, George A. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (03) :969-976
[46]   Interplay between β-lactamases and new β-lactamase inhibitors [J].
Bush, Karen ;
Bradford, Patricia A. .
NATURE REVIEWS MICROBIOLOGY, 2019, 17 (05) :295-306
[47]   Multidrug Resistant Acinetobacter baumannii: Resistance by Any Other Name Would Still be Hard to Treat [J].
Butler, David A. ;
Biagi, Mark ;
Tan, Xing ;
Qasmieh, Samah ;
Bulman, Zackery P. ;
Wenzler, Eric .
CURRENT INFECTIOUS DISEASE REPORTS, 2019, 21 (12)
[48]   Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC [J].
Cabot, Gabriel ;
Bruchmann, Sebastian ;
Mulet, Xavier ;
Zamorano, Laura ;
Moya, Bartolome ;
Juan, Carlos ;
Haussler, Susanne ;
Oliver, Antonio .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (06) :3091-3099
[49]   The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant Pseudomonas aeruginosa Infections [J].
Caffrey, Aisling R. ;
Appaneal, Haley J. ;
Liao, J. Xin ;
Piehl, Emily C. ;
Lopes, Vrishali ;
Dillon, Ryan J. ;
Puzniak, Laura A. ;
LaPlante, Kerry L. .
ANTIBIOTICS-BASEL, 2022, 11 (05)
[50]  
Cai T., 2020, Int J Antimicrob Agents, V56